Bonnet J, Tournayre S, Anitcheou J, et al
All I can say is that she has rejoined the pool. Shortly afterward, Williams was asked directly about the speculation in an interview on the Today show, but declined to give a clear answer: Its not a yes, and its not a no
It may be a fit for patients who: Have appetite regulation challenges Have signs of insulin resistance Have struggled with repeated weight loss attempts Need stronger metabolic support Have not responded as expected to other approaches Have a medical history that supports tirzepatide use Can tolerate the medication appropriately Tirzepatide may be appealing because of its dual-hormone mechanism, but stronger does not always mean better for every person
The short answer is yes compounded semaglutide remains legal in May 2026 through 503A patient-specific compounding by state-licensed pharmacies
If $299 or $399 per month is not sustainable for your financial situation, starting at the introductory rate and then struggling to continue is worse than choosing a different option from the beginning
Medical supervision supports your progress
